Transcode Therapeutics EV/EBITDA
The EV/EBITDA (Enterprise Value to EBITDA) of Transcode Therapeutics (RNAZ) as of Oct 12, 2026 is 0.33. In the previous year, EV/EBITDA (Enterprise Value to EBITDA) was -0.17 — a change of -300.64% (higher).
Get this data via API
Financial Data API
EV/EBITDA
0.33
YoY
-300.64%
Last updated:
The Transcode Therapeutics EV/EBITDA history
3 Years
10 Years
25 Years
Max
| YEAR | EV/EBITDA | YoY |
|---|---|---|
| 0.33 | -300.64% | |
| -0.17 | -48.41% | |
| -0.32 | +67.54% | |
| -0.19 | -112.56% | |
| 1.52 | -111.29% | |
| -13.48 | -33.49% | |
| -20.27 | -11.51% | |
| -22.91 | — |
Transcode Therapeutics Stock analysis
Frequently Asked Questions about Transcode Therapeutics stock
EV/EBITDA (Enterprise Value to EBITDA) of Transcode Therapeutics is 0.33 in 2025.
EV/EBITDA (Enterprise Value to EBITDA) of Transcode Therapeutics changed from -0.17 to 0.33, representing a -300.64% change. The value is higher than the previous year.
On Eulerpool you can find the complete historical development of EV/EBITDA (Enterprise Value to EBITDA) Transcode Therapeutics since 2006 – with annual values, charts, and detailed analysis.
The EV/EBITDA ratio is a widely used valuation metric that compares a company's enterprise value to its EBITDA. It normalizes for differences in capital structure, taxation, and depreciation policies.
To evaluate EV/EBITDA (Enterprise Value to EBITDA)'s, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for EV/EBITDA (Enterprise Value to EBITDA).
A 'good' varies by industry and company stage. On Eulerpool, you can compare EV/EBITDA (Enterprise Value to EBITDA)'s Transcode Therapeutics with sector peers and the industry average to assess whether it is attractive.
Valuation — Transcode Therapeutics
All Key Metrics — Transcode Therapeutics
Valuation
Income Statement
Margins
Balance Sheet
- Total Assets
- Current Assets
- Cash & Equivalents
- Receivables
- Inventory
- Property, Plant & Equipment
- Goodwill
- Intangible Assets
- Equity
- Liabilities
- Debt
- Current Liabilities
- Long-term Debt
- Short-term Debt
- Retained Earnings
- Book Value per Share
- Tangible Book Value per Share
- Working Capital
- Investments
- Accounts Payable
- Non-Current Assets
- Short-Term Investments
- Long-Term Investments
- Net Debt
- Treasury Stock
- Minority Interest
- Deferred Tax Liabilities
- Net Tangible Assets
- Goodwill/Assets
- Intangibles/Assets
Cash Flow
- Operating Cash Flow
- Capital Expenditures
- Free Cash Flow
- FCF per Share
- Dividends Paid
- Share Buybacks
- Investing Cash Flow
- Financing Cash Flow
- CapEx / Revenue
- Cash Flow per Share
- Stock-Based Compensation
- Change in Working Capital
- Acquisitions (Net)
- Net Change in Cash
- CapEx/OCF
- FCF/Net Income
- FCF Conversion
- Cash Conversion
- Total Shareholder Payout
- CapEx/D&A
Profitability
- ROE
- ROA
- ROCE
- ROIC
- Asset Turnover
- Inventory Turnover
- Receivables Turnover
- Days Sales Outstanding
- Days Inventory Outstanding
- Days Payable Outstanding
- Cash Conversion Cycle
- CROIC
- Gross Profit/Assets
- Fixed Asset Turnover
- Equity Turnover
- Working Capital Turnover
- Payables Turnover
- Capital Intensity
- Receivables/Revenue
- Inventory/Revenue
- EBIT/Assets
Leverage
Growth
- Revenue Growth
- Revenue CAGR 3Y
- Revenue CAGR 5Y
- Revenue CAGR 10Y
- Earnings Growth
- EPS Growth
- EBIT Growth
- EBIT CAGR 3Y
- EBIT CAGR 5Y
- EBIT CAGR 10Y
- Dividend Growth
- FCF Growth
- Book Value Growth
- Earnings CAGR 3Y
- Earnings CAGR 5Y
- Earnings CAGR 10Y
- EPS CAGR 3Y
- EPS CAGR 5Y
- EBITDA Growth YoY
- EBITDA CAGR 3Y
- EBITDA CAGR 5Y
- Gross Profit Growth
- OCF Growth YoY
- Employee Growth
- Dividend CAGR 3Y
- Dividend CAGR 5Y
- Dividend CAGR 10Y
- Asset Growth
- Equity Growth
- Debt Growth
- CapEx Growth
- FCF CAGR 3Y
- FCF CAGR 5Y
- Market Cap Growth
- Share Count Growth